Affinage

EZR

Ezrin · UniProt P15311

Audit flag: ungrounded claim
Length
586 aa
Mass
69.4 kDa
Annotated
2026-06-09
32 papers in source corpus 13 papers cited in narrative 23 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 4/5 claims corpus-supported (80%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

EZR (ezrin) is a membrane–cytoskeletal linker and signaling scaffold whose activation couples plasma-membrane lipid cues to cortical actin organization, cell shape, and motility. The protein is held in a closed autoinhibited state by an intramolecular FERM–C-terminal domain (CTD) interface; PI(4,5)P2 binding to the F1/F3 FERM subdomains outcompetes other phospholipids and destabilizes the F2–CTD interface, allowing spontaneous CTD dissociation, after which Thr567 phosphorylation prevents reassociation and locks the open active conformation, while EBP50 competes for the freed F2–F3 surface. PI(4,5)P2 binding alone is sufficient to recruit ezrin to membranes. T567 phosphorylation is driven by upstream kinases including PKCα within a hypoxia–autophagy axis (PMID:31775562) and by LOK, which is itself restrained by ERK; this ERK–LOK–ezrin module controls Rho activity through ARHGAP18 recruitment and governs stress-fiber assembly during migration. Active ezrin sustains cortical actin contractility and protects cells against osmotic rupture, with its inhibition redirecting actin from the cortex to formin-dependent stress fibers. EZR expression is transcriptionally controlled by Sp1 and AP-1 (c-Jun/c-Fos) acting downstream of MEK/ERK signaling (PMID:19164283, PMID:25915860) and by epigenetic activation through SMYD3-mediated H3K4 methylation (PMID:26980013). In cancer cells, ezrin acts upstream of RhoA/Rac1/Cdc42 GTPases and sustains FAK/AKT and STAT3 signaling to promote proliferation, migration, invasion, and therapy resistance (PMID:37304008, PMID:34627255, PMID:41621788). A specific PTM, K60 succinylation reversed by the desuccinylase SIRT7, links ezrin to melanin synthesis (PMID:38933605). In vivo, ezrin is required for bile duct fluid regulation, and loss produces cholestatic hepatic injury (PMID:28049946), and a missense EZR variant with zebrafish knockout data implicates ezrin in lens epithelial cell differentiation in congenital cataract (PMID:38563525).

Mechanistic history

Synthesis pass · year-by-year structured walk · 14 steps
  1. 2009 High

    Established how EZR transcription is controlled, identifying the cis-elements and transcription factors that set ezrin expression levels.

    Evidence Promoter deletion/mutation luciferase reporters, EMSA, and ChIP in esophageal carcinoma cells mapping Sp1/AP-1 binding downstream of MEK-ERK

    PMID:19164283

    Open questions at the time
    • Does not address ezrin protein activation or function
    • Promoter behavior characterized in a single cancer cell context
  2. 2011 Medium

    Extended transcriptional regulation by mapping a distal enhancer element governing VIL2/EZR promoter activity.

    Evidence Deletion-construct luciferase reporters in HEK-293 cells

    PMID:21585339

    Open questions at the time
    • Trans-acting factors binding the enhancer not identified
    • Single method, single cell line
  3. 2015 Medium

    Connected an extracellular stimulus (phorbol ester) to isoform-specific EZR induction through MEK/ERK-driven Sp1/AP-1 occupancy of the V1 promoter.

    Evidence Promoter-luciferase, ChIP, U0126 inhibition, and siRNA migration assays in ESCC cells

    PMID:25915860

    Open questions at the time
    • Does not resolve why variant 2 is unresponsive
    • Functional rescue of migration only partial
  4. 2016 Medium

    Identified an epigenetic input to EZR expression, showing SMYD3 occupies the EZR promoter to stimulate transcription.

    Evidence ChIP, RNAi knockdown, and in vitro/in vivo functional assays

    PMID:26980013

    Open questions at the time
    • Did not define the chromatin mark deposited
    • Mechanism of SMYD3 recruitment unresolved
  5. 2017 Medium

    Demonstrated an in vivo physiological requirement for ezrin in bile duct function, beyond its cancer-cell roles.

    Evidence Vil2kd/kd knockdown mouse model with histology, liver function assays, and UDCA treatment

    PMID:28049946

    Open questions at the time
    • Molecular link between ezrin and biliary fluid regulation not defined
    • Single model system
  6. 2018 Medium

    Resolved how SMYD3 is targeted to EZR, showing antisense lncRNA EZR-AS1 recruits SMYD3 to deposit H3K4me3 and engages RNA Pol II.

    Evidence Co-IP, ChIP, RNA pulldown, reporter assays, and xenografts

    PMID:29253179

    Open questions at the time
    • Concerns transcriptional regulation, not ezrin protein mechanism
    • Single lab
  7. 2019 Medium

    Placed ezrin T567 phosphorylation within a hypoxia–autophagy–PKCα signaling axis controlling tumor-initiating cell self-renewal.

    Evidence Autophagy-gene and kinase knockdown, pharmacological inhibition, phospho-immunostaining, and in vivo tumor initiation

    PMID:31775562

    Open questions at the time
    • No in vitro reconstitution of PKCα–ezrin kinase-substrate relationship
    • How autophagy couples to PKCα activation unclear
  8. 2021 Low

    Linked ezrin to FAK/AKT signaling as a driver of pancreatic cancer proliferation and invasion.

    Evidence siRNA knockdown, Western blot, proliferation and Transwell assays

    PMID:34627255

    Open questions at the time
    • No direct biochemical interaction between EZR and FAK shown
    • Single lab phenotypic readout
  9. 2022 Low

    Positioned ezrin upstream of Rho-family GTPases in cancer cell motility.

    Evidence siRNA knockdown with RhoA/Rac1/Cdc42 activation pulldown and migration/invasion assays

    PMID:37304008

    Open questions at the time
    • Mechanism connecting ezrin to GTPase activation not defined
    • Single lab
  10. 2024 Medium

    Identified K60 succinylation as a SIRT7-regulated PTM coupling ezrin to melanin biosynthesis, broadening ezrin regulation beyond T567 phosphorylation.

    Evidence Co-IP, IP, Western blot, rescue, and tyrosinase/melanin assays in melanocytes

    PMID:38933605

    Open questions at the time
    • Structural/functional consequence of K60 succinylation on ezrin conformation unknown
    • Succinyltransferase not identified
  11. 2024 Medium

    Implicated ezrin in lens epithelial differentiation, linking a human EZR missense variant to congenital cataract.

    Evidence Linkage analysis, whole-exome sequencing, and TALEN-mediated zebrafish knockout with histology

    PMID:38563525

    Open questions at the time
    • Functional impact of the P471L variant on ezrin activity not assayed
    • Single family
  12. 2025 Medium

    Defined the structural-mechanistic basis of ezrin activation, showing PI(4,5)P2 binding triggers CTD dissociation that T567 phosphorylation then stabilizes.

    Evidence Enhanced-sampling molecular dynamics, free-energy calculations, and biochemical validation (preprint)

    Open questions at the time
    • Computational model awaits full peer-reviewed experimental confirmation
    • EBP50 competition step inferred from simulation
  13. 2025 Medium

    Established an ERK–LOK–ezrin–ARHGAP18–Rho cascade controlling stress-fiber assembly and directed migration.

    Evidence Molecular perturbations, live-cell imaging, kinase assays, and epistasis in migrating cells (preprint)

    Open questions at the time
    • Awaits peer review
    • Quantitative contribution of LOK versus other ezrin kinases unresolved
  14. 2025 Low

    Demonstrated ezrin's role in cortical mechano-protection, where its activity maintains cortical contractility against osmotic rupture.

    Evidence Ezrin and formin small-molecule inhibitors, hypo-osmotic shock, live imaging, and traction force in CHO cells (preprint)

    Open questions at the time
    • Single preprint, pharmacological approach
    • Direct ezrin–formin relationship not biochemically defined

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the lipid-triggered structural activation, the multiple PTMs (T567 phosphorylation, K60 succinylation), and the diverse downstream effectors (Rho GTPases, FAK/AKT, STAT3, Wnt/β-catenin) are integrated into context-specific ezrin functions in vivo remains unresolved.
  • No unified model linking activation state to specific effector engagement
  • Most cancer-pathway links lack direct ezrin–effector biochemistry
  • Several key mechanisms exist only as preprints

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008092 cytoskeletal protein binding 2 GO:0008289 lipid binding 2 GO:0060090 molecular adaptor activity 1
Localization
GO:0005886 plasma membrane 3 GO:0005856 cytoskeleton 2
Pathway
R-HSA-74160 Gene expression (Transcription) 3 R-HSA-162582 Signal Transduction 2
Partners
ARHGAP18EBP50FOXF2ITGB4NHERF1PRKCASLK

Evidence

Reading pass · 23 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2019 Hypoxia-induced autophagy drives phosphorylation of EZR (ezrin) at Thr567, mediated by PRKCA/PKCα as the upstream kinase; knockdown of autophagy genes ATG5, BNIP3, BNIP3L, or BECN1 reversed this phosphorylation, establishing a hypoxia-autophagy-PKC-EZR signaling axis that regulates tumor-initiating cell self-renewal. Gene knockdown (shRNA/siRNA), pharmacological inhibition, phospho-specific immunostaining, in vivo tumor initiation assays Autophagy Medium 31775562
2009 Transcription of the EZR/VIL2 gene in esophageal carcinoma cells is controlled by Sp1 and AP-1 (c-Jun/c-Fos) binding to a minimal promoter region (-87/-32); these transcription factors bind their respective sites and are activated downstream of the MEK1/2-ERK1/2 signaling pathway. Luciferase reporter with deletion/site-directed mutants, EMSA, chromatin immunoprecipitation, pharmacological inhibitors The Journal of biological chemistry High 19164283
2016 The histone methyltransferase SMYD3 directly binds to the EZR promoter region and stimulates EZR transcription; ChIP assay confirmed SMYD3 occupancy at the EZR promoter, and SMYD3 knockdown suppressed EZR expression, cell proliferation, migration, and invasion. Chromatin immunoprecipitation (ChIP), RNAi knockdown, in vitro and in vivo functional assays Human pathology Medium 26980013
2018 Antisense lncRNA EZR-AS1 recruits SMYD3 to a GC-rich region downstream of the EZR promoter, causing H3K4me3 enrichment and enhanced EZR transcription; EZR-AS1 also forms a complex with RNA polymerase II to activate EZR transcription. Co-immunoprecipitation, ChIP, RNA pulldown, reporter assays, in vivo xenograft Nucleic acids research Medium 29253179
2015 TPA (phorbol ester) induces over-expression of EZR/VIL2 variant 1 (but not variant 2) in ESCC cells via activation of MEK/ERK1/2 signaling, which increases c-Jun and Sp1 binding to the AP-1 and Sp1 composite TPA-responsive element in the VIL2 V1 promoter; MEK inhibitor U0126 blocks this induction, and ezrin silencing partially reverses TPA-promoted cell migration. Promoter-luciferase assays, ChIP, pharmacological inhibitors (U0126), siRNA knockdown, migration assays PloS one Medium 25915860
2011 A DNA enhancer element for the VIL2/EZR gene was mapped to the -1297/-1186 region upstream of the VIL2 promoter; this element functions in a position- and orientation-dependent manner to enhance VIL2 promoter activity in HEK-293 cells. Luciferase reporter assays with deletion constructs in transiently transfected HEK-293 cells Cell biology international Medium 21585339
2021 EZR promotes pancreatic cancer cell proliferation, migration, and invasion via activation of the FAK/AKT signaling pathway; EZR knockdown suppressed these phenotypes and reduced FAK protein levels and downstream signaling. siRNA knockdown, Western blot, CCK-8 assay, Transwell assay Cancer cell international Low 34627255
2022 EZR knockdown inhibited RhoA, Rac1, and Cdc42 activity in breast cancer cells, as confirmed by RhoA activation assays, placing EZR upstream of these small GTPases in regulating cancer cell migration and invasion. siRNA knockdown, RhoA/Rac1/Cdc42 activation (pulldown) assays, migration and invasion assays Oncology research Low 37304008
2024 SIRT7, a desuccinylase, suppresses succinylation of EZR at the Lys60 site; SIRT7 knockdown promoted EZR succinylation at K60, and EZR overexpression induced higher melanin synthesis in melanocytes, whereas EZR knockdown blocked SIRT7-loss-induced melanin synthesis, placing EZR downstream of SIRT7-regulated succinylation in melanin biosynthesis. Co-immunoprecipitation, immunoprecipitation, Western blot, rescue experiments, tyrosinase activity assay, melanin content measurement Clinical, cosmetic and investigational dermatology Medium 38933605
2017 Ezrin (Vil2) is required for proper bile duct fluidity and alkalinity regulation; ezrin-knockdown (Vil2kd/kd) mice exhibit severe hepatic injury resembling intrahepatic cholestatic disease, and UDCA treatment ameliorated hepatic function and fibrosis in these mice independently of biliary bicarbonate secretion. Vil2kd/kd knockdown mouse model, histology, liver function assays, gene expression analysis, in vitro cholangiocyte cytotoxicity Biological & pharmaceutical bulletin Medium 28049946
2024 A missense variant (P471L) in EZR was identified in a family with congenital nuclear cataract; EZR knockout in zebrafish using TALENs caused developmental delays manifesting as multilayered lens epithelial cells with abnormal proliferation patterns, indicating ezrin is required for enucleation and differentiation of lens epithelial cells. Linkage analysis, whole-exome sequencing, TALEN-mediated zebrafish knockout, histology, immunohistochemistry Ophthalmic genetics Medium 38563525
2026 EZR depletion in breast cancer cells suppressed STAT3 Tyr705 phosphorylation and downstream pro-survival signaling; STAT3 activation partially rescued EZR-loss phenotypes (reduced proliferation, migration, invasion, increased apoptosis), establishing that EZR sustains STAT3 signaling to drive metastatic competence and paclitaxel resistance. Stable EZR silencing (shRNA), phospho-kinase profiling, immunoblot, STAT3 activation rescue, orthotopic xenograft, lung colonization model, paclitaxel-resistant subline generation Life sciences Medium 41621788
2025 ERK phosphorylates the C-terminal tail of the Ezrin-activating kinase LOK, inhibiting LOK's activation of Ezrin in the cell body; this releases Ezrin's inhibition of Rho (via ARHGAP18 recruitment) and promotes stress fiber assembly for cell migration, establishing an ERK-LOK-Ezrin-ARHGAP18-Rho signaling cascade. Molecular perturbations, live-cell imaging, kinase activity assays, epistasis experiments in migrating cells bioRxivpreprint Medium
2025 PI(4,5)P2 binding to the Ezrin FERM domain (F1 and F3 subdomains) outcompetes other phospholipids and triggers a conformational rearrangement that destabilizes the FERM F2-CTD interface, enabling spontaneous dissociation of the non-phosphorylated C-terminal domain (CTD); T567 phosphorylation subsequently impedes FERM-CTD reassociation, stabilizing the open active conformation. EBP50 competes with the CTD for F2-F3 FERM binding after CTD dissociation. Enhanced sampling molecular dynamics (metadynamics), free energy calculations, contact-map collective variables, biochemical validation bioRxivpreprint Medium
2025 Both PC1 and PC2 polycystins co-immunoprecipitate Ezrin; acute loss of polycystins reduced Ezrin protein abundance and caused mis-localization of active Ezrin away from the apical surface in renal epithelial cells, and PKC inhibition phenocopied this loss, implicating the polycystin complex in regulating Ezrin phosphorylation and apical cell shape. Co-immunoprecipitation, inducible Pkd1/Pkd2 knockout, immunofluorescence, 3D tubuloid culture, pharmacological inhibitors (NSC668394, PKC inhibitor) bioRxivpreprint Low
2025 Phactr4 loss leads to Ezrin hyperphosphorylation in macrophages, and ezrin inhibition reverses the membrane protrusion defects caused by Phactr4 knockdown, placing Ezrin downstream of the PP1-Phactr4 phosphatase axis in controlling lamellipodial dynamics and macrophage migration. siRNA knockdown, pharmacological ezrin inhibition, live-cell imaging, epistasis experiments bioRxivpreprint Low
2025 In bleb-based migration of metastatic melanoma cells under confinement, CD44 and ERM proteins (including Ezrin) restrict EGFR mobility within a membrane-apposed cortical actin meshwork at the bleb rear, establishing a rear-to-front EGFR-PI3K-Rac1 activity gradient required for bleb stability and polarized migration. High-resolution time-lapse imaging, protein activity biosensors, optogenetics, specific molecular perturbations bioRxivpreprint Low
2024 Erbin physically interacts with NHERF1, Ezrin, and HER2 in actin-rich membrane protrusions of HER2-positive breast cancer cells; Erbin knockdown disrupted the HER2/NHERF1/Ezrin/HSP90 protein complex, reducing HER2 signaling, and inhibition of Ezrin disrupted Erbin's ability to interact with HER2, establishing Ezrin as a scaffold component of this signaling complex. Co-immunoprecipitation, knockdown, immunofluorescence in SKBR3 cells and MMTV-Neu mammary glands bioRxivpreprint Low
2024 Integrin beta 4 (ITGB4) directly interacts with Ezrin (EZR) as confirmed by co-immunoprecipitation and co-immunofluorescence; ITGB4 knockdown decreased EZR expression at both mRNA and protein levels, and EZR overexpression rescued the pro-tumorigenic phenotypes suppressed by ITGB4 silencing, establishing ITGB4 as an upstream regulator of EZR that activates Wnt/β-catenin signaling in colorectal cancer. Co-immunoprecipitation, co-immunofluorescence, RNA-seq, Western blot, functional rescue assays, xenograft model bioRxivpreprint Low
2025 PI(4,5)P2 asymmetrically incorporated into supported lipid bilayers retains functionality and recruits ezrin to the membrane, demonstrating that ezrin binding to PI(4,5)P2 is sufficient for membrane recruitment in a reconstituted system. Supported lipid bilayer reconstitution, FRAP, fluorescence microscopy bioRxivpreprint Low
2025 Inhibition of ezrin phosphorylation (using small molecule inhibitors) reduced mechano-protection of cells against hypo-osmotic shock by weakening cortical actin contractility and shifting actin organization from the cortex to stress fibers via formin-mediated actin polymerization; formin inhibition (SMIFH2) prevented this stress fiber increase and blocked the subsequent increase in cell rupture rates. Small molecule ezrin inhibitors, formin inhibitor (SMIFH2), hypo-osmotic shock assay, live-cell imaging, traction force measurements bioRxivpreprint Low
2024 SLK and Ezrin both significantly influence actin cytoskeleton architecture; differential effects were observed between protein knockdown and dephosphorylation, suggesting phosphorylation-independent roles for Ezrin in modulating actin dynamics beyond its canonical activation by T567 phosphorylation. siRNA knockdown, pharmacological inhibitors, actin structure imaging in HaCaT cells bioRxivpreprint Low
2028 FOXF2 transcription factor directly interacts with EZR and inhibits EZR transcriptional expression; FOXF2 knockdown enhanced ESCC cell growth and metastasis in vitro and in vivo, and suppression of ERBB2 signaling function was shown to be downstream of EZR regulation by FOXF2. Western blot, qRT-PCR, plasmid transfection, lentiviral infection, co-IP (implied by 'directly interacted'), migration/invasion assay, xenograft model Translational cancer research Low 39816549

Source papers

Stage 0 corpus · 32 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 Hypoxia-induced autophagy drives colorectal cancer initiation and progression by activating the PRKC/PKC-EZR (ezrin) pathway. Autophagy 147 31775562
2018 The interaction of lncRNA EZR-AS1 with SMYD3 maintains overexpression of EZR in ESCC cells. Nucleic acids research 85 29253179
2019 Long noncoding RNA ANRIL regulates endothelial cell activities associated with coronary artery disease by up-regulating CLIP1, EZR, and LYVE1 genes. The Journal of biological chemistry 59 30655286
2009 Sp1 and AP-1 regulate expression of the human gene VIL2 in esophageal carcinoma cells. The Journal of biological chemistry 56 19164283
2016 SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma. Human pathology 43 26980013
2021 Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control. Frontiers in immunology 35 34084172
2021 EZR promotes pancreatic cancer proliferation and metastasis by activating FAK/AKT signaling pathway. Cancer cell international 30 34627255
2018 Long noncoding RNA EZR-AS1 promotes tumor growth and metastasis by modulating Wnt/β-catenin pathway in breast cancer. Experimental and therapeutic medicine 22 30186463
2021 TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR. Cell death & disease 17 34429402
2020 lncRNA EZR‑AS1 knockdown represses proliferation, migration and invasion of cSCC via the PI3K/AKT signaling pathway. Molecular medicine reports 16 33236153
2020 The Activity of KIF14, Mieap, and EZR in a New Type of the Invasive Component, Torpedo-Like Structures, Predetermines the Metastatic Potential of Breast Cancer. Cancers 15 32679794
2019 Silencing of lncRNA EZR-AS1 inhibits proliferation, invasion, and migration of colorectal cancer cells through blocking transforming growth factor β signaling. Bioscience reports 13 31693738
2023 Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer. Cancer gene therapy 11 37949944
2017 Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2kd/kd Mice. Biological & pharmaceutical bulletin 11 28049946
2023 Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine. Cancer gene therapy 10 37666898
2022 Integrative multiomics analysis identifies a metastasis-related gene signature and the potential oncogenic role of EZR in breast cancer. Oncology research 10 37304008
2020 Long Noncoding RNA EZR-AS1 Regulates the Proliferation, Migration, and Apoptosis of Human Venous Endothelial Cells via SMYD3. BioMed research international 10 32596350
2015 12-O-Tetradecanoylphorbol-13-Acetate Induces Up-Regulated Transcription of Variant 1 but Not Variant 2 of VIL2 in Esophageal Squamous Cell Carcinoma Cells via ERK1/2/AP-1/Sp1 Signaling. PloS one 10 25915860
2021 Epithelial-mesenchymal transition and cancer stem cell interactions in breast phyllodes tumours: immunohistochemical evaluation of EZH2, EZR, HMGA2, CD24 and CD44 in correlation with outcome analysis. Journal of clinical pathology 6 33627375
2024 SIRT7 Inhibits Melanin Synthesis of PIG1 and PIG3V by Suppressing the Succinylation of EZR. Clinical, cosmetic and investigational dermatology 5 38933605
2021 EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma. Virchows Archiv : an international journal of pathology 5 34128116
2020 Next Generation Sequencing Reveals a Synchronous Trilateral Lung Adenocarcinoma Case with Distinct Driver Alterations of EGFR 19 Deletion or EGFR 20 Insertion or EZR-ROS1 Fusion. OncoTargets and therapy 5 33328738
2025 Comprehensive in silico characterization of nonsynonymous SNPs in the human ezrin (EZR) gene and their role in disease pathogenesis. Biochemistry and biophysics reports 3 40129965
2023 Silencing lncRNA EZR‑AS1 induces apoptosis and attenuates the malignant properties of lung adenocarcinoma cells. Acta biochimica Polonica 2 37722090
2018 Deciphering brain-specific transcriptomic expression of Ezr, Rad and Msn genes in the development of Mus musculus. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 2 29906485
2024 Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer. Scientific reports 1 38684875
2011 Identification of the VIL2 enhancer in human embryonic kidney cells. Cell biology international 1 21585339
2026 Ezrin (EZR) promotes breast cancer progression and drug resistance: Molecular mechanisms involving STAT3 activation. Life sciences 0 41621788
2026 EZR-ROS1 rearrangement as a novel mechanism of acquired resistance to EGFR-TKIs in NSCLC: a case report and literature review. Frontiers in immunology 0 41668738
2024 Variant in EZR leads to defects in lens development. Ophthalmic genetics 0 38563525
2024 FOXF2 may inhibit esophageal squamous cell carcinoma growth and metastasis by regulating the EZR-ERBB2 axis. Translational cancer research 0 39816549
1992 PvuII RFLP in the cytovillin gene (VIL2) on human chromosome 6q. Nucleic acids research 0 1347924

Missed literature

Know a paper Affinage missed for EZR? Flag it for the maintainers and the community.

No submissions yet.